Immunosuppression and Immunotherapy in Cancer : International symposium at the Ulm University Hospital.

[Immunosuppression and Immunotherapy in Cancer : International symposium at the Ulm University Hospital]. HNO. 2020 Feb;68(2):69-70 Authors: Hoffmann TK PMID: 32047977 [PubMed - in process]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research

Related Links:

Purpose of review To report the available information on the current status and future direction of the use of checkpoint inhibitors as novel immunotherapeutic agents in bladder cancer. Recent findings In the past 3 years, five immunotherapies targeting programmed cell death 1 (Pembrolizumab and Durvalumab) or programmed cell death-ligand 1 (PD-L1) (Atezolizumab, nivolumab and Avelumab) pathways have been approved in second-line setting for patients who progressed during or after cisplatin-based chemotherapy. According to the most recent update, these patients should be PD-L1-positive to be eligible for immunotherapy....
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: BLADDER CANCER: Edited by Juan Palou and Óscar Rodríguez Faba Source Type: research
There ’s a new cell-based cancer immunotherapy on the block.
Source: The Scientist - Category: Science Tags: Bio Business Source Type: news
Contributor : Yu ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensDescription of breast cancer infiltrating lymphocyte through large scale single cell sequencing.While it has been well-recognized that T-cell mediated adaptive cellular immunity plays important roles in cancer immune response and tumor control, the roles of B lymphocytes in tumor development and therapy have only been proposed until recently, and are still mostly controversial. To gain mechanistic insights into the origin and dynamics of tumor infiltrated immune cells, especially B lymphocytes, we combined single ce...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Contributors : Samir Devalaraja ; Tsun K To ; Ian W Folkert ; Ramakrishnan Natesan ; Zahidul Alam ; Minghong Li ; Yuma Tada ; Konstantin Budagyan ; Mai Dang ; Li Zhai ; Graham P Lobel ; Gabrielle E Ciotti ; T K Eisinger-Mathason ; Irfan A Asangani ; Kristy Weber ; M C Simon ; Malay HaldarSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe immunosuppressive tumor microenvironment (TME) is a major barrier to immunotherapy. Within solid tumors, why monocytes preferentially differentiate into immunosuppressive tumor associated macrophages (TAMs) but not immunostimulatory dendritic cells (...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
Conclusion: 89Zr-IAB22M2C imaging is safe and has favorable kinetics for early imaging. Biodistribution suggests successful targeting of CD8+ T-cell–rich tissues. The observed targeting of tumor lesions suggests this may be informative for CD8+ T-cell accumulation within tumors. Further evaluation is under way.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Translational Source Type: research
AbstractNeuropathic pain (NeP) is an intractable pain caused by a lesion or disease of the somatosensory nervous system. NeP is often challenging to manage because most of the mechanisms remain to be elucidated. Recent investigations in the field of autoimmune neurology have demonstrated that specific autoantibodies against antigens in the somatosensory pathway can cause NeP. Detection of pathogenic autoantibodies in NeP adds to the understanding of the mechanism of pain, which might aid in the development of novel immunotherapies. Therefore, it is necessary to explore novel NeP ‐related autoantibodies to improve the man...
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: REVIEW ARTICLE Source Type: research
(eLife) Scientists have developed a new immunotherapy that eradicates solid tumours in mice without adverse side effects, according to a new study published today in eLife.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In conclusion, comprehensive bioinformatics identified 17 immune genes as potential prognostic biomarkers, which might be potential candidates of immunotherapy targets in BC patients. The current study depicted regulatory network between transcription factors and immune genes, which was helpful to deepen the understanding of immune regulatory mechanisms for BC cancer. Two artificial intelligence survival predictive systems are available at and These novel a...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
More News: Cancer | Cancer & Oncology | ENT & OMF | Hospitals | Immunotherapy